Logo image of NDVA.CA

INDIVA LTD (NDVA.CA) Stock Fundamental Analysis

TSX-V:NDVA - TSX Venture Exchange - CA45580J1012 - Common Stock - Currency: CAD

0.03  -0.01 (-14.29%)

Fundamental Rating

2

Taking everything into account, NDVA scores 2 out of 10 in our fundamental rating. NDVA was compared to 34 industry peers in the Pharmaceuticals industry. NDVA may be in some trouble as it scores bad on both profitability and health. NDVA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NDVA has reported negative net income.
In the past year NDVA has reported a negative cash flow from operations.
In the past 5 years NDVA always reported negative net income.
In the past 5 years NDVA reported 4 times negative operating cash flow.
NDVA.CA Yearly Net Income VS EBIT VS OCF VS FCFNDVA.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -11.73%, NDVA is in line with its industry, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
ROA -11.73%
ROE N/A
ROIC N/A
ROA(3y)-25.75%
ROA(5y)-29.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NDVA.CA Yearly ROA, ROE, ROICNDVA.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

1.3 Margins

Looking at the Gross Margin, with a value of 29.21%, NDVA is in line with its industry, outperforming 45.71% of the companies in the same industry.
NDVA's Gross Margin has improved in the last couple of years.
NDVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y45.31%
NDVA.CA Yearly Profit, Operating, Gross MarginsNDVA.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K

More info and screens

0

2. Health

2.1 Basic Checks

NDVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NDVA has more shares outstanding
Compared to 5 years ago, NDVA has more shares outstanding
NDVA has about the same debt/assets ratio as last year.
NDVA.CA Yearly Shares OutstandingNDVA.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
NDVA.CA Yearly Total Debt VS Total AssetsNDVA.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

NDVA has an Altman-Z score of -1.80. This is a bad value and indicates that NDVA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NDVA (-1.80) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.8
ROIC/WACCN/A
WACC6.06%
NDVA.CA Yearly LT Debt VS Equity VS FCFNDVA.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

NDVA has a Current Ratio of 0.70. This is a bad value and indicates that NDVA is not financially healthy enough and could expect problems in meeting its short term obligations.
NDVA's Current ratio of 0.70 is on the low side compared to the rest of the industry. NDVA is outperformed by 74.29% of its industry peers.
NDVA has a Quick Ratio of 0.70. This is a bad value and indicates that NDVA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NDVA (0.45) is worse than 68.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.45
NDVA.CA Yearly Current Assets VS Current LiabilitesNDVA.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

6

3. Growth

3.1 Past

NDVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.50%, which is quite impressive.
Looking at the last year, NDVA shows a small growth in Revenue. The Revenue has grown by 7.30% in the last year.
The Revenue has been growing by 264.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
Revenue 1Y (TTM)7.3%
Revenue growth 3Y36.88%
Revenue growth 5Y264.6%
Sales Q2Q%-0.89%

3.2 Future

NDVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
NDVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.68% yearly.
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.86%
Revenue Next 2Y11.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NDVA.CA Yearly Revenue VS EstimatesNDVA.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
NDVA.CA Yearly EPS VS EstimatesNDVA.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 -0.05 -0.1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NDVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NDVA.CA Price Earnings VS Forward Price EarningsNDVA.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NDVA.CA Per share dataNDVA.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

A more expensive valuation may be justified as NDVA's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NDVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDIVA LTD

TSX-V:NDVA (6/12/2024, 7:00:00 PM)

0.03

-0.01 (-14.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-23 2024-05-23
Earnings (Next)08-27 2024-08-27
Inst Owners0.1%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.86M
Analysts80
Price Target0.15 (400%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.19
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.21%
FCFM N/A
ROA(3y)-25.75%
ROA(5y)-29.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y45.31%
F-Score5
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 722.14%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.45
Altman-Z -1.8
F-Score5
WACC6.06%
ROIC/WACCN/A
Cap/Depr(3y)221.04%
Cap/Depr(5y)519.22%
Cap/Sales(3y)2.84%
Cap/Sales(5y)253.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.3%
Revenue growth 3Y36.88%
Revenue growth 5Y264.6%
Sales Q2Q%-0.89%
Revenue Next Year15.86%
Revenue Next 2Y11.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year332.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.9%
OCF growth 3YN/A
OCF growth 5YN/A